Statins do not help prevent Alzheimer’s disease, but another cholesterol-controlling drug just might. Obicetrapib blocks cholesteryl esters being transferred from the “good” high-density lipoproteins ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Computational biology has put the human brain vasculature in its crosshairs. On July 23 in Neuron, scientists led by Andrew Yang, University of California, San Francisco, report a multiomic approach ...

Up-and-coming Alzheimer’s blood tests may soon be used for people with Down’s syndrome. In a longitudinal biomarker study of adults with three copies of ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

Some scientists have long suspected that neuronal viruses such as herpes can hasten or even cause dementia. What about infections that don’t attack neurons directly? The COVID-19 pandemic offered ...

Missense mutations that derail SORL1 trafficking cause AD. Other variants shift AD risk in East Asians and Europeans. SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in ...

Lomecel-B is a preparation of multipotent stem and progenitor cells isolated from donated bone marrow of young healthy adults, and expanded in culture. The cells are administered by intravenous ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

On September 26, 2024, the National Institute on Aging (NIA) announced that Masliah had been removed from his position as scientific director of the institute’s neuroscience division after a ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...